Search: WFRF:(Maria Langkilde Anna) >
The dapagliflozin a...
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics
-
- Wheeler, David C. (author)
- UCL, Dept Renal Med, London, England.
-
- Stefansson, Bergur, V (author)
- AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
-
- Batiushin, Mikhail (author)
- Rostov State Med Univ, Dept Nephrol, Rostov Na Donu, Russia.
-
show more...
-
- Bilchenko, Oleksandr (author)
- Kharkiv Med Acad Postgrad Educ, Kharkiv, Ukraine.
-
- Cherney, David Z., I (author)
- Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada.;Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada.
-
- Chertow, Glenn M. (author)
- Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA.;Stanford Univ, Dept Med, Sch Med, Stanford, CA USA.
-
- Douthat, Walter (author)
- Hosp Privado Univ Cordoba, Dept Nephrol, Cordoba, Argentina.
-
- Dwyer, Jamie P. (author)
- Vanderbilt Univ, Med Ctr, Nashville, TN USA.
-
- Escudero, Elizabeth (author)
- Cayetano Heredia Univ, Hosp Arzobispo Loayza, Div Nephrol, Lima, Peru.
-
- Pecoits-Filho, Roberto (author)
- Pontificia Univ Catolica Parana, Sch Med, Curitiba, Parana, Brazil.;Arbor Res Collaborat Hlth, Ann Arbor, MI USA.
-
- Furuland, Hans (author)
- Uppsala universitet,Njurmedicin
-
- Gorriz, Jose Luis (author)
- Univ Valencia, Univ Clin Hosp, Dept Nephrol, INCLIVA, Valencia, Spain.
-
- Greene, Tom (author)
- Univ Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USA.
-
- Haller, Hermann (author)
- Hannover Med Sch, Hannover, Germany.
-
- Hou, Fan Fan (author)
- Southern Med Univ, Natl Clin Res Ctr Kidney Dis, Dept Med, Div Nephrol, Guangzhou, Peoples R China.
-
- Kang, Shin-Wook (author)
- Yonsei Univ, Dept Internal Med, Div Nephrol, Coll Med, Seoul, South Korea.
-
- Isidto, Rey (author)
- Healthlink Med Dent Surg Clin & Diagnost Ctr, Iloilo, Philippines.
-
- Khullar, Dinesh (author)
- Max Super Special Hosp, Dept Nephrol & Renal Transplant Med, New Delhi, India.
-
- Mark, Patrick B. (author)
- Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
-
- McMurray, John J., V (author)
- Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
-
- Kashihara, Naoki (author)
- Kawasaki Med Sch, Dept Nephrol & Hypertens, Okayama, Japan.
-
- Nowicki, Michal (author)
- Med Univ Lodz, Dept Nephrol Hypertens & Kidney Transplantat, Lodz, Poland.
-
- Persson, Frederik (author)
- Steno Diabet Ctr Copenhagen, Gentofte, Denmark.
-
- Correa-Rotter, Ricardo (author)
- Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico.
-
- Rossing, Peter (author)
- Steno Diabet Ctr Copenhagen, Gentofte, Denmark.;Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
-
- Toto, Robert D. (author)
- UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA.
-
- Umanath, Kausik (author)
- Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA.;Wayne State Univ, Div Nephrol & Hypertens, Detroit, MI USA.
-
- Van Bui, Pham (author)
- Pham Ngoc Thach Med Univ, Ho Chi Minh City, Vietnam.
-
- Wittmann, Istvan (author)
- Univ Pecs, Dept Med 2, Med Sch, Pecs, Hungary.;Univ Pecs, Nephrol Diabet Ctr, Med Sch, Pecs, Hungary.
-
- Lindberg, Magnus (author)
- AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
-
- Sjostrom, C. David (author)
- AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
-
- Langkilde, Anna Maria (author)
- AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
-
- Heerspink, Hiddo J. L. (author)
- Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
-
show less...
-
UCL, Dept Renal Med, London, England AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (creator_code:org_t)
- 2020-08-30
- 2020
- English.
-
In: Nephrology, Dialysis and Transplantation. - OXFORD ENGLAND : Oxford University Press (OUP). - 0931-0509 .- 1460-2385. ; 35:10, s. 1700-1711
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://academic.oup...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- chronic kidney disease
- dapagliflozin
- randomized controlled clinical trial
- sodium-glucose co-transporter-2 inhibitor
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Wheeler, David C ...
-
Stefansson, Berg ...
-
Batiushin, Mikha ...
-
Bilchenko, Oleks ...
-
Cherney, David Z ...
-
Chertow, Glenn M ...
-
show more...
-
Douthat, Walter
-
Dwyer, Jamie P.
-
Escudero, Elizab ...
-
Pecoits-Filho, R ...
-
Furuland, Hans
-
Gorriz, Jose Lui ...
-
Greene, Tom
-
Haller, Hermann
-
Hou, Fan Fan
-
Kang, Shin-Wook
-
Isidto, Rey
-
Khullar, Dinesh
-
Mark, Patrick B.
-
McMurray, John J ...
-
Kashihara, Naoki
-
Nowicki, Michal
-
Persson, Frederi ...
-
Correa-Rotter, R ...
-
Rossing, Peter
-
Toto, Robert D.
-
Umanath, Kausik
-
Van Bui, Pham
-
Wittmann, Istvan
-
Lindberg, Magnus
-
Sjostrom, C. Dav ...
-
Langkilde, Anna ...
-
Heerspink, Hiddo ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Urology and Neph ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Nephrology, Dial ...
- By the university
-
Uppsala University